La Jolla Pharmaceutical Company is dedicated to the development of treatments that significantly improve outcomes in patients with life-threatening diseases. Our current efforts focus on the clinical evaluation of GCS-100, a galectin antagonist, as a treatment for chronic organ disease and LJPC-501, an antagonist of the renin-angiotensin pathway, as a treatment for hepatorenal syndrome, a life-threatening form of progressive renal failure in patients with liver cirrhosis or fulminant liver failure. In addition, our experienced team of scientists are expanding our pipeline by developing innovative new therapies to treat diseases of the liver and lung as well as cancer.
Current Clinical Studies: A Phase 2 Study of Weekly Doses of GCS-100 in Patients with Chronic Kidney Disease
ASN Poster : Poster November 7, 2013
BIO Investor Forum
Corporate Presentation: BIO Investor Forum Presentation October 8, 2013
Webcast Link: Bio Investor Forum Webcast